Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by TheBearInTheWoodson Sep 11, 2020 6:54pm
132 Views
Post# 31547267

RE:RE:Composition vs Utility Patent Question

RE:RE:Composition vs Utility Patent QuestionSCENERIO #2

ACME DRUGS has DRUG A, it has been used  for treatment of the dizziness caused by cerebral infarction sequela or cerebral hemorrhage sequela. The company has been making said drug for 50 year and has a Composition Patent for the drug.

BIG ALS DRUGS has found out that DRUG A can be used to treat Lung Inflammation so has applied for a method of use patent to treat lung inflammation using a slow release IV drug " To be developed"

Any doctor could give a prescription for ACME drugs for lung inflammation now and BIG AL could not get the patent he filed for. 

But if you want big als company, he will raise money at .40 make that .35 when the price is .56 and give 8% commision when doing so ....here at big als drugs we are here for the little guy!
<< Previous
Bullboard Posts
Next >>